創薬サービス市場：プロセス、タイプ、薬剤タイプ、治療領域、地域別、2024年～2031年

創薬サービス市場の評価、2024年～2031年

革新的な治療法やバイオテクノロジーのブレークスルーに対するニーズの高まりとともに、研究開発に関連するコストを削減し、新薬の市場投入までの時間を短縮するために製薬会社がアウトソーシングを行う傾向が強まっていることが、創薬サービス市場を牽引しています。Verified Market Researchのアナリストによると、創薬サービス市場は、2024年には約128億2,000万米ドルを超え、予測期間中に287億1,000万米ドルの評価に達すると推定されます。

ゲノミクスとプロテオミクスの急速な発展は、医薬品研究開発への支出の増加とともに、創薬サービス市場を牽引しています。これにより、市場は2024年から2031年にかけてCAGR11.70%で成長します。

創薬サービス市場定義/概要

創薬サービスとは、新規化合物を同定・開発するために専門家である開発業務受託機関（CRO）が行う研究開発業務のアウトソーシングです。これらのサービスには、標的同定、アッセイ開発、ハイスループットスクリーニング、ヒット・ツー・リード最適化、臨床試験など、幅広い業務が含まれます。

さらに、創薬サービスには、新薬開発の加速、先端技術や専門知識へのアクセスの提供、新薬調査方法の効率化、新薬の上市に必要なコストと時間の大幅な削減など、幅広い用途があります。これらのサービスは、CROの専門的なスキルやリソースを活用しながら、研究開発努力の合理化、リスクの低減、中核的な強みへの集中を目指す製薬企業にとって極めて重要です。

研究開発投資の増加は市場の成長をどのように促進するか？

製薬業界では、多額の投資を背景に研究開発へのコミットメントを高めており、これが主な推進力となっています。これらの投資は、特に腫瘍学や神経学など、アンメット・メディカル・ニーズを満たす革新的な治療薬の開発を目的としています。慢性疾患の世界の増加により、継続的な技術革新が必要とされているため、製薬会社は創薬サービスの一部を専門業者に委託し、効率と技術革新を高めています。

ハイスループット・スクリーニング、バイオインフォマティクス、ゲノミクスの技術向上が創薬サービス市場を牽引しています。これらの技術は、既存のアプローチよりも安価で迅速な速度で、大規模な化学ライブラリーの迅速なスクリーニングを可能にします。さらに、AIと機械学習は、薬剤の挙動予測、薬剤設計の最適化、実行可能な治療薬候補の同定において重要性を増しており、薬剤開発段階に関連する時間とコストを削減しています。

さらに、大手製薬企業やバイオテクノロジー企業は、戦略的提携やアウトソーシングを通じて、CROの専門的知識や高度な技術をますます活用するようになっています。創薬のアウトソーシングにより、企業は中核能力に集中し、コストを効果的にコントロールし、新治療の市場投入までの時間を短縮することができます。この方法は、大規模な医薬品開発活動を行うためのリソースを社内に持たない中小のバイオテクノロジー企業にとって特に重要です。

創薬サービス市場に影響を与える主な課題とは？

創薬は高額でリスクの高い事業であり、新しい治療法の開発には数十億米ドルの費用がかかり、10年以上かかることも少なくないです。特に初期段階での失敗率は高く、投資意欲をそぎ、プロジェクトの財政的存続を危うくします。このような出費や危険は、大手製薬企業のような資金力を持たない中小企業にとっては特に大きな負担となります。

さらに、知的財産（IP）の保護は、競争の激しい創薬の世界では極めて重要です。しかし、知的財産権の管理は、特に外部委託の創薬研究プロジェクトでよくあるように、多数のパートナーが関与する場合には困難です。知的財産の所有権や特許権をめぐって対立が生じ、法的な問題に発展したり、新薬の開発や商業化の妨げになったりすることもあります。

目次

第1章 創薬サービス市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 創薬サービス市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 創薬サービス市場：プロセス別

• 概要
• ターゲット選択
• ターゲットバリデーション
• ヒット・トゥ・リードの同定
• リードの最適化
• 候補化合物の検証

第6章 創薬サービス市場：タイプ別

• 概要
• メディシナルケミストリーサービス
• 生物学サービス
• 薬物代謝・薬物動態（DMPK）サービス
• 医薬品タイプ別市場
• 低分子医薬品
• 生物学的製剤

第7章 世界の創薬市場：薬剤タイプ別

• 概要
• 低分子医薬品
• 生物学的製剤

第8章 創薬サービス市場：治療領域別

• 概要
• がん領域
• 神経
• 感染症・免疫系疾患
• 消化器系疾患
• 心血管疾患
• その他の治療領域

第9章 創薬サービス市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東

第10章 創薬サービス市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• Abbott Laboratories Inc.
• Advinus Therapeutics
• Agilent Technologies Ubiquigent
• Albany Molecular Research Inc.
• AstraZeneca PLC
• Aurigene
• Bayer AG
• Charles River Laboratories International
• ChemBridge Corporation
• Covance

第12章 付録

• 関連調査

Drug Discovery Services Market Valuation - 2024-2031

The growing trend of outsourcing by pharmaceutical companies to decrease costs associated with research and development and speed up time-to-market for new pharmaceuticals, along with the growing need for innovative therapies and biotechnology breakthroughs, are driving the drug discovery services market. According to the analyst from Verified Market Research, the drug discovery services market is estimated to reach a valuation of USD 28.71 Billion over the forecast subjugating around USD 12.82 Billion valued in 2024.

The rapid developments in genomics and proteomics, together with increased spending in pharmaceutical R&D, are driving the drug discovery services market, as is the requirement for specialized knowledge in drug development procedures. It enables the market to grow at aCAGR of 11.70% from 2024 to 2031.

Drug Discovery Services Market: Definition/ Overview

Drug discovery services are the outsourced research and development activities performed by specialist contract research organizations (CROs) to identify and develop new pharmaceutical compounds. These services encompass a wide range of operations, including target identification, assay development, high-throughput screening, hit-to-lead optimization, and clinical testing.

Furthermore, drug discovery services have a wide range of applications, including accelerating the development of new medications, providing access to advanced technologies and expertise, improving the efficiency of drug research processes, and significantly lowering the costs and time required to bring new drugs to market. These services are critical for pharmaceutical companies looking to streamline their R&D efforts, reduce risks, and focus on core strengths while harnessing the specialized skills and resources of CROs.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How will Increase in R&D Investments Drive the Growth of the Market?

The pharmaceutical industry's rising commitment to R&D, backed by significant investments, is a primary driver. These investments are intended to develop innovative therapeutics to treat unmet medical needs, particularly in oncology and neurology. The increased global frequency of chronic diseases needs ongoing innovation, prompting pharmaceutical companies to outsource portions of their drug discovery services to specialist service providers, therefore increasing efficiency and innovation.

Technological improvements in high-throughput screening, bioinformatics, and genomics are driving the drug discovery services market. These technologies enable the rapid screening of large chemical libraries at cheaper prices and faster rates than existing approaches. Furthermore, AI and machine learning are becoming increasingly important in predicting drug behavior, optimizing drug design, and identifying viable therapeutic candidates, thus decreasing the time and cost associated with drug development phases.

Furthermore, big pharma and biotech businesses are increasingly leveraging CROs' specialized knowledge and advanced technology through strategic cooperation and outsourcing. Outsourcing drug discovery enables businesses to focus on core capabilities, effectively control costs, and reduce time to market for new treatments. This method is especially important for smaller biotech companies that lack the internal resources to perform large-scale drug development activities.

What are the Primary Challenges Impacting the Drug Discovery Services Market?

Drug discovery is an expensive and high-risk enterprise, with the development of a new treatment frequently costing billions of dollars and taking more than a decade. The failure rate is particularly high in the early phases, discouraging investment and putting the project's financial viability at risk. These expenses and hazards are especially onerous for smaller businesses that lack the financial resources of larger pharmaceutical enterprises.

Furthermore, protecting intellectual property (IP) is critical in the competitive world of drug discovery. However, managing IP rights is difficult, especially when numerous partners are involved, as is common in outsourced drug research projects. Conflicts over intellectual property ownership and patent rights may arise, resulting in legal issues and impeding the development and commercialization of novel drugs.

Category-Wise Acumens

What are the Factors Supporting the Dominance of Small Molecules in the Market?

According to VMR analysis, the small molecules segment is estimated to hold the largest market share in the drug type segment during the forecast period. Small-molecule drugs are typically less expensive to manufacture and scale than biologics. They can be generated in huge quantities using chemical procedures, making them more easily produced and distributed. Because of their low cost, small molecules are especially appealing to pharmaceutical businesses seeking to optimize their return on investment.

Small molecules have a lengthy history in the pharmaceutical industry, thus there are well-established regulatory channels for their development and approval. This familiarity streamlines medication discovery, decreases regulatory approval uncertainty, and shortens time-to-market, making them a popular choice among pharmaceutical corporations.

Furthermore, small molecules easily permeate cells and influence a wide range of biological targets, making them useful for treating a variety of disorders, both chronic and acute. This broad applicability bolsters ongoing research and development efforts, allowing them to maintain their lead in the drug discovery services market.

How does Oncology Propel the Growth of the Drug Discovery Services Market?

The oncology segment is estimated to dominate the drug discovery services market during the forecast period. The global rise in cancer incidence is a significant motivator for the emphasis on oncology in drug discovery. As cancer remains the biggest cause of death worldwide, there is a strong desire for novel and more effective cancer treatments. This need encourages pharmaceutical companies and research organizations to engage extensively in oncology research, resulting in the growth of this market segment.

The evolution of precision medicine, particularly in oncology, has had a substantial impact on medication discovery. Advances in genetic sequencing and molecular diagnostics enable more precise and individualized cancer treatments. This emphasis on unique patient profiles and tumor genetics has moved drug research efforts toward more personalized solutions, improving the efficacy and success rates of oncology drugs.

Furthermore, oncology has one of the most extensive drug development pipelines in all therapeutic fields. The continual discovery of new targets and routes for cancer treatment drives continued research and development. Also, the high likelihood of market approval and commercial success for oncology medications encourages investment in this sector, reinforcing its market share domination in drug discovery services.

Country/Region-wise Acumens

How Does the Rising Biopharmaceutical Sector Drive the Market in the Asia Pacific?

According to VMR analyst, North America is estimated to dominate the drug discovery services market during the forecast period. North America has a highly developed biopharmaceutical sector, with the United States dominating in terms of innovation, drug development, and market approvals. This region is home to several of the world's leading pharmaceutical and biotech companies, which continue to invest in medication discovery and development. This climate promotes robust R&D activity, attracting large investments and partnerships to propel the market ahead.

Furthermore, the presence of advanced research infrastructures, such as world-class universities, research institutes, and cutting-edge laboratories, facilitates large-scale drug development initiatives. North America receives major government and private financing for therapeutic research in fields such as oncology, neurology, and cardiovascular disease, which is crucial to the continued discovery of new drugs.

What are the Primary Factors Driving the Drug Discovery Services in Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the drug discovery services market during the forecast period. Many countries in the Asia-Pacific region are experiencing rapid economic growth and higher healthcare spending. As these economies flourish, more resources are directed toward healthcare, including investments in innovative medical treatments and research centers. This economic development promotes the growth of the pharmaceutical and biotechnology sectors, increasing demand for drug discovery services.

Furthermore, the Asia Pacific region is experiencing an increase in the prevalence of chronic diseases such as diabetes, cardiovascular disease, and cancer, which is being driven by changing lifestyles and an aging population. This increase in disease prevalence is driving up the need for innovative and effective treatment medications, strengthening the regional drug discovery services market.

Competitive Landscape

The competitive landscape of the drug discovery services market is characterized by a wide range of vendors providing specialized services at various stages of the drug development pipeline. Furthermore, there is a growing trend toward customization and tailored service models to meet the individual needs of clients, which adds to the competitiveness.

Some of the prominent players operating in the drug discovery services market include:

Abbott Laboratories, Inc.

Advinus Therapeutics

Agilent Technologies Ubiquigent

Albany Molecular Research, Inc.

AstraZeneca PLC

Aurigene

Bayer AG

Charles River Laboratories International

ChemBridge Corporation

Covance

Latest Developments

In February 2023, Charles River Laboratories signed a multi-program agreement with Pioneering Medicines, a Flagship Pioneering (US) initiative, to use its Logica Al platform for small-molecule drug discovery.

In February 2023, Evotec SE and Related Sciences signed a multi-target drug discovery deal. The two firms sought to choose, research, and develop precisely targeted medications to address unmet patient needs.

In January 2023, Charles River Laboratories purchased SAMDI Tech, Inc., which provides label-free HTS solutions for drug discovery research. The acquisition provided CRL with experience in label-free HTS MS platforms and resulted in a broad library of drug discovery options.

TABLE OF CONTENTS

1 INTRODUCTION OF DRUG DISCOVERY SERVICES MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 DRUG DISCOVERY SERVICES MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 DRUG DISCOVERY SERVICES MARKET, BY PROCESS

• 5.1 Overview
• 5.2 Target Selection
• 5.3 Target Validation
• 5.4 Hit-To-Lead Identification
• 5.5 Lead Optimization
• 5.6 Candidate Validation

6 DRUG DISCOVERY SERVICES MARKET, BY TYPE

• 6.1 Overview
• 6.2 Medicinal Chemistry Services
• 6.3 Biology Services
• 6.4 Drug Metabolism and Pharmacokinetics (DMPK)
• 6.5 Market, by Drug Type
• 6.6 Small- molecule Drugs
• 6.7 Biologic Drugs

7 GLOBAL DRUG DISCOVERY MARKET, BY DRUG TYPE

• 7.1 Overview
• 7.2 Small Molecule Drugs
• 7.3 Biologic Drugs

8 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA

• 8.1 Overview
• 8.2 Oncology
• 8.3 Neurology
• 8.4 Infectious and Immune System Diseases
• 8.5 Digestive System Diseases
• 8.6 Cardiovascular Diseases
• 8.7 Other Therapeutic Areas

9 DRUG DISCOVERY SERVICES MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East

10 DRUG DISCOVERY SERVICES MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories Inc.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Advinus Therapeutics
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Agilent Technologies Ubiquigent
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Albany Molecular Research Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 AstraZeneca PLC
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Aurigene
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Bayer AG
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Charles River Laboratories International
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 ChemBridge Corporation
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Covance
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research